Intravenous Colistin Versus Intravenous Colistin Plus Nebulized Colistin in VAP Due MDR Acinetobacter Baumannii

Hospitales Universitarios Virgen del Rocío

Status and phase: Unknown; Phase 3

Conditions: Cross Infection; Pneumonia, Bacterial

Treatments: Drug: Colistin and saline solution; Drug: Colistin

Study type: Interventional

Funder types: Other

Identifiers

NCT00645723

COL\VAP

Details and patient eligibility

About

Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.

Full description

Compare the clinical efficiency evaluated by the treatment of the intravenous colistin plus inhaled colistin opposite to the treatment with colistin intravenous plus inhaled saline solution in patients with VAP due to baumannii carbapenems resistant.

Enrollment: 67 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnose of VAP due A. baumannii or A. baumannii and another microorganism carbapenems resistant.
• Clinical Pulmonary Infection Score (CPIS) > 6

Exclusion criteria

• Allergy to colistin.
• Asthma
• Shock status
• Diagnose of VAP due A. baumannii colistin resistant.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

67 participants in 2 patient groups, including a placebo group

A

Experimental group

Description:

Intravenous colistin and nebulized colistin

Treatment:

Drug: Colistin

B

Placebo Comparator group

Description:

intravenous colistin and saline solution nebulized

Treatment:

Drug: Colistin and saline solution